Literature DB >> 32676826

Trends in Morbidity and Mortality Following Colectomy Among Patients with Ulcerative Colitis in the Biologic Era (2002-2013): A Study Using the National Inpatient Sample.

Babatunde Olaiya1, Benjamin D Renelus2, Mikolaj Filon3, Sumona Saha4.   

Abstract

BACKGROUND: Total abdominal colectomy (TAC) is a treatment modality of last recourse for patients with severe and/or refractory ulcerative colitis (UC). The goal of this study is to evaluate temporal trends and treatment outcomes following TAC among hospitalized UC patients in the biologic era.
METHODS: We queried the National Inpatient Sample (NIS) to identify patients older than 18 years with a primary diagnosis of ulcerative colitis (UC) who underwent TAC between 2002 and 2013. We evaluated postoperative morbidity and mortality as outcomes of interest. Logistic regression was used to explore factors associated with postoperative morbidity and mortality after TAC.
RESULTS: A weighted total of 307,799 UC hospitalizations were identified. Of these, 27,853 (9%) resulted in TAC. Between 2002 and 2013, hospitalizations for UC increased by over 70%; however, TAC rates dropped significantly from 111.1 to 77.1 colectomies per 1000 UC admissions. Overall, 2.2% of patients died after TAC. Mortality rates after TAC decreased from 3.5% in 2002 to 1.4% in 2013. Conversely, morbidity rates were stable throughout the study period. UC patients with emergent admissions, higher comorbidity scores and who had TAC in low volume colectomy hospitals had poorer outcomes. Regardless of admission type, outcomes were worse if TAC was performed more than 24 h after admission.
CONCLUSIONS: Despite increased hospitalizations for UC, rates of TAC have declined during the post-biologic era. For UC patients who undergo TAC, mortality has declined significantly while morbidity remains stable. Older age, race, emergent admissions and delayed surgery are predictive factors of both postoperative morbidity and mortality.

Entities:  

Keywords:  Colectomy; National Inpatient Sample; Ulcerative colitis

Mesh:

Substances:

Year:  2020        PMID: 32676826     DOI: 10.1007/s10620-020-06474-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  34 in total

1.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

Authors:  William J Sandborn; Gert van Assche; Walter Reinisch; Jean-Frederic Colombel; Geert D'Haens; Douglas C Wolf; Martina Kron; Mary Beth Tighe; Andreas Lazar; Roopal B Thakkar
Journal:  Gastroenterology       Date:  2011-11-04       Impact factor: 22.682

2.  Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000.

Authors:  Conor G Loftus; Edward V Loftus; W Scott Harmsen; Alan R Zinsmeister; William J Tremaine; L Joseph Melton; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2007-03       Impact factor: 5.325

3.  Incidence and Prevalence of Crohn's Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010.

Authors:  Raina Shivashankar; William J Tremaine; W Scott Harmsen; Edward V Loftus
Journal:  Clin Gastroenterol Hepatol       Date:  2016-11-14       Impact factor: 11.382

4.  ACG Clinical Guideline: Ulcerative Colitis in Adults.

Authors:  David T Rubin; Ashwin N Ananthakrishnan; Corey A Siegel; Bryan G Sauer; Millie D Long
Journal:  Am J Gastroenterol       Date:  2019-03       Impact factor: 10.864

5.  Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.

Authors:  Chinyu Su; Bruce A Salzberg; James D Lewis; Julius J Deren; Asher Kornbluth; David A Katzka; Robert B Stein; Douglas R Adler; Gary R Lichtenstein
Journal:  Am J Gastroenterol       Date:  2002-10       Impact factor: 10.864

6.  Perceived Emotional and Psychological Impact of Ulcerative Colitis on Outpatients in Spain: UC-LIFE Survey.

Authors:  Antonio López-Sanromán; Daniel Carpio; Xavier Calvet; Cristina Romero; Luis Cea-Calvo; Berta Juliá; Federico Argüelles-Arias
Journal:  Dig Dis Sci       Date:  2016-11-05       Impact factor: 3.199

7.  Postoperative complications and mortality following colectomy for ulcerative colitis.

Authors:  Shanika de Silva; Christopher Ma; Marie-Claude Proulx; Marcelo Crespin; Belle S Kaplan; James Hubbard; Martin Prusinkiewicz; Andrew Fong; Remo Panaccione; Subrata Ghosh; Paul L Beck; Anthony Maclean; Donald Buie; Gilaad G Kaplan
Journal:  Clin Gastroenterol Hepatol       Date:  2011-07-30       Impact factor: 11.382

8.  Infliximab in pediatric ulcerative colitis: two-year follow-up.

Authors:  Petar Mamula; Jonathan E Markowitz; Louis J Cohen; Daniel von Allmen; Robert N Baldassano
Journal:  J Pediatr Gastroenterol Nutr       Date:  2004-03       Impact factor: 2.839

9.  Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

Authors:  William J Sandborn; Brian G Feagan; Colleen Marano; Hongyan Zhang; Richard Strauss; Jewel Johanns; Omoniyi J Adedokun; Cynthia Guzzo; Jean-Frederic Colombel; Walter Reinisch; Peter R Gibson; Judith Collins; Gunnar Järnerot; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2013-06-14       Impact factor: 22.682

10.  Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.

Authors:  Carlos Taxonera; Cristina Rodríguez; Federico Bertoletti; Luís Menchén; Julia Arribas; Mónica Sierra; Lara Arias; Pilar Martínez-Montiel; Alba Juan; Eva Iglesias; Alicia Algaba; Noemí Manceñido; Montserrat Rivero; Manuel Barreiro-de Acosta; Pilar López-Serrano; Federico Argüelles-Arias; Ana Gutierrez; David Busquets; Javier P Gisbert; David Olivares; Marta Calvo; Cristina Alba
Journal:  Inflamm Bowel Dis       Date:  2017-08       Impact factor: 5.325

View more
  3 in total

1.  Periplaneta americana extract ameliorates dextran sulfate sodium-induced ulcerative colitis via immunoregulatory and PI3K/AKT/NF-κB signaling pathways.

Authors:  Lianli Ni; Qian Lu; Miao Tang; Lu Tao; Hairong Zhao; Chenggui Zhang; Yun Yu; Xiumei Wu; Heng Liu; Ri Cui
Journal:  Inflammopharmacology       Date:  2022-03-18       Impact factor: 4.473

2.  Prevention of ulcerative colitis by Huangqin decoction: reducing the intestinal epithelial cell apoptosis rate through the IFN-γ/JAK/ETS signalling pathway.

Authors:  Xiaowei Mo; Kairui Tang; Lijing Deng; Xingyi Zhou; Xiaojuan Li; Yupei Zhang; Jing Wang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

Review 3.  Essential updates 2020/2021: Colorectal diseases (benign)-Current topics in the surgical and medical treatment of benign colorectal diseases.

Authors:  Hiroshi Sawayama; Yuji Miyamoto; Naoya Yoshida; Hideo Baba
Journal:  Ann Gastroenterol Surg       Date:  2022-01-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.